reported that AT III use was associated with lower thrombosis incidence but higher in-hospital mortality, which may be related to early mortality in critically ill patients and shorter ECMO durations, making it difficult to accurately estimate AT III’s true efficacy [16]. The gene discussed is SERPINC1; the disease is Venous thrombosis.